116 related articles for article (PubMed ID: 30347155)
1. Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.
Zhao J; Zhang D; Zhang W; Stashko MA; DeRyckere D; Vasileiadi E; Parker RE; Hunter D; Liu Q; Zhang Y; Norris-Drouin J; Li B; Drewry DH; Kireev D; Graham DK; Earp HS; Frye SV; Wang X
J Med Chem; 2018 Nov; 61(22):10242-10254. PubMed ID: 30347155
[TBL] [Abstract][Full Text] [Related]
2. UNC5293, a potent, orally available and highly MERTK-selective inhibitor.
Zheng H; Zhao J; Li B; Zhang W; Stashko MA; Minson KA; Huey MG; Zhou Y; Earp HS; Kireev D; Graham DK; DeRyckere D; Frye SV; Wang X
Eur J Med Chem; 2021 Aug; 220():113534. PubMed ID: 34038857
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors.
McIver AL; Zhang W; Liu Q; Jiang X; Stashko MA; Nichols J; Miley MJ; Norris-Drouin J; Machius M; DeRyckere D; Wood E; Graham DK; Earp HS; Kireev D; Frye SV; Wang X
ChemMedChem; 2017 Feb; 12(3):207-213. PubMed ID: 28032464
[TBL] [Abstract][Full Text] [Related]
4. Effects of MERTK Inhibitors UNC569 and UNC1062 on the Growth of Acute Myeloid Leukaemia Cells.
Koda Y; Itoh M; Tohda S
Anticancer Res; 2018 Jan; 38(1):199-204. PubMed ID: 29277773
[TBL] [Abstract][Full Text] [Related]
5. MerTK activity is not necessary for the proliferation of glioblastoma stem cells.
Hoque M; Wai Wong S; Recasens A; Abbassi R; Nguyen N; Zhang D; Stashko MA; Wang X; Frye S; Day BW; Baell J; Munoz L
Biochem Pharmacol; 2021 Apr; 186():114437. PubMed ID: 33571503
[TBL] [Abstract][Full Text] [Related]
6. A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of binding.
Pflug A; Schimpl M; Nissink JWM; Overman RC; Rawlins PB; Truman C; Underwood E; Warwicker J; Winter-Holt J; McCoull W
Biochem J; 2020 Nov; 477(22):4443-4452. PubMed ID: 33119085
[TBL] [Abstract][Full Text] [Related]
7. Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development.
Park TH; Bae SH; Bong SM; Ryu SE; Jang H; Lee BI
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114206
[TBL] [Abstract][Full Text] [Related]
8. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
[TBL] [Abstract][Full Text] [Related]
9. Near infrared imaging of Mer tyrosine kinase (MERTK) using MERi-SiR reveals tumor associated macrophage uptake in metastatic disease.
Miller MA; Kim E; Cuccarese MF; Plotkin AL; Prytyskach M; Kohler RH; Pittet MJ; Weissleder R
Chem Commun (Camb); 2017 Dec; 54(1):42-45. PubMed ID: 29185561
[TBL] [Abstract][Full Text] [Related]
10. Development of [
Wong SW; Vivash L; Mudududdla R; Nguyen N; Hermans SJ; Shackleford DM; Field J; Xue L; Aprico A; Hancock NC; Haskali M; Stashko MA; Frye SV; Wang X; Binder MD; Ackermann U; Parker MW; Kilpatrick TJ; Baell JB
Eur J Med Chem; 2021 Dec; 226():113822. PubMed ID: 34563964
[TBL] [Abstract][Full Text] [Related]
11. Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N
Woodward HL; Innocenti P; Cheung KJ; Hayes A; Roberts J; Henley AT; Faisal A; Mak GW; Box G; Westwood IM; Cronin N; Carter M; Valenti M; De Haven Brandon A; O'Fee L; Saville H; Schmitt J; Burke R; Broccatelli F; van Montfort RLM; Raynaud FI; Eccles SA; Linardopoulos S; Blagg J; Hoelder S
J Med Chem; 2018 Sep; 61(18):8226-8240. PubMed ID: 30199249
[TBL] [Abstract][Full Text] [Related]
12. MERTK as a novel therapeutic target in head and neck cancer.
von Mässenhausen A; Sanders C; Thewes B; Deng M; Queisser A; Vogel W; Kristiansen G; Duensing S; Schröck A; Bootz F; Brossart P; Kirfel J; Heasley L; Brägelmann J; Perner S
Oncotarget; 2016 May; 7(22):32678-94. PubMed ID: 27081701
[TBL] [Abstract][Full Text] [Related]
13. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract][Full Text] [Related]
14. Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy.
Nissink JWM; Bazzaz S; Blackett C; Clark MA; Collingwood O; Disch JS; Gikunju D; Goldberg K; Guilinger JP; Hardaker E; Hennessy EJ; Jetson R; Keefe AD; McCoull W; McMurray L; Olszewski A; Overman R; Pflug A; Preston M; Rawlins PB; Rivers E; Schimpl M; Smith P; Truman C; Underwood E; Warwicker J; Winter-Holt J; Woodcock S; Zhang Y
J Med Chem; 2021 Mar; 64(6):3165-3184. PubMed ID: 33683117
[TBL] [Abstract][Full Text] [Related]
15. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).
Ma F; Liu P; Lei M; Liu J; Wang H; Zhao S; Hu L
Eur J Med Chem; 2017 Feb; 127():72-86. PubMed ID: 28038328
[TBL] [Abstract][Full Text] [Related]
17. MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.
Huelse JM; Fridlyand DM; Earp S; DeRyckere D; Graham DK
Pharmacol Ther; 2020 Sep; 213():107577. PubMed ID: 32417270
[TBL] [Abstract][Full Text] [Related]
18. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
19. Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library.
Zhang Q; Liu Y; Gao F; Ding Q; Cho C; Hur W; Jin Y; Uno T; Joazeiro CA; Gray N
J Am Chem Soc; 2006 Feb; 128(7):2182-3. PubMed ID: 16478150
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
